Nivolumab/Ipilimumab Phase 3 Trial for Rare Sarcoma Subtype Completes Primary…

The Phase 3 trial (NCT04741438) investigating the combination of nivolumab and ipilimumab for patients with sarcoma of rare subtype reached its primary completion on 2025-02-28. This randomized study enrolled 96 participants to evaluate the efficacy of the immunotherapy combination.

Background

The trial focuses on patients diagnosed with metastatic or unresectable advanced sarcoma of rare subtype. These patients had either been previously treated with an anthracycline-based regimen or lacked appropriate standard therapy. The study aims to explore new treatment options for this challenging patient population.

Trial design

The study, identified as NCT04741438, is a Phase 3, randomized, open-label trial. It enrolled 96 participants diagnosed with metastatic or unresectable advanced sarcoma of rare subtype. Participants were randomized into two arms: an experimental arm receiving the combination of nivolumab and ipilimumab for a maximum of 24 months, and a control arm receiving pazopanib oral tablet. The study's objective is to determine if the combination of nivolumab and ipilimumab is more efficient than pazopanib alone in this patient population.

What this means

The primary completion of this Phase 3 trial signifies a crucial step in evaluating the potential of nivolumab and ipilimumab for patients with sarcoma of rare subtype. While specific efficacy data is not yet available, the completion indicates that the study has reached a point where primary data collection for its main objectives is finalized. Future data releases will provide insights into whether the combination therapy offers a more effective treatment option compared to pazopanib for this challenging cancer.

Source

The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT04741438, titled "Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype," was recorded on 2025-02-28 on clinicaltrials.gov.